文献速递脊柱关节炎

司库奇尤单抗可持续改善强直性脊柱炎患者疲劳:两项III期随机对照试验长期结果

Secukinumab and Sustained Reduction in Fatigue in Patients With Ankylosing Spondylitis: Long-Term Results of Two Phase III Randomized Controlled Trials.
PubMed 文献 · Arthritis Care Res (Hoboken) · 2022-03-10

基于MEASURE 1(最长3年)和MEASURE 2(最长2年)两项III期随机对照试验,司库奇尤单抗150 mg在16周时较安慰剂显著改善强直性脊柱炎患者FACIT-F疲劳评分(P<0.05),并持续至156周和104周;疲劳应答率在抗TNF初治和抗TNF应答不足/不耐受患者中均较高。

要点

  • 司库奇尤单抗150 mg在MEASURE 1和2中16周时FACIT-F评分较基线改善显著优于安慰剂。
  • 疲劳改善持续至MEASURE 1第156周和MEASURE 2第104周。
  • 第156周/104周疲劳应答率分别为75.6%和81.4%,抗TNF初治与经治患者结果一致。

核心结论

  • 司库奇尤单抗可快速且持续改善强直性脊柱炎患者疲劳长达3年,且不受既往抗TNF暴露影响。

研究设计与样本

  • MEASURE 1和MEASURE 2两项III期随机对照试验,活动性强直性脊柱炎患者随机接受司库奇尤单抗或安慰剂。
  • MEASURE 1为静脉10 mg/kg负荷后皮下150 mg,观察至3年;MEASURE 2为皮下150 mg,观察至2年。
  • 患者为抗TNF初治或抗TNF应答不足/不耐受,疲劳采用FACIT-F量表评估。

主要发现

  • 第16周时司库奇尤单抗组FACIT-F评分较基线改善显著优于安慰剂(两项研究均P<0.05)。
  • 改善持续至MEASURE 1第156周和MEASURE 2第104周。
  • 第16周疲劳应答(FACIT-F改善≥4)患者比例司库奇尤单抗150 mg显著高于安慰剂(MEASURE 1 P<0.05;MEASURE 2 P<0.01)。
  • 第156周(MEASURE 1)和第104周(MEASURE 2)疲劳应答率分别为75.6%和81.4%;抗TNF初治为74.3%和84.6%,抗TNF经治为81.3%和75.0%。
  • 疲劳应答与ASAS20/40、ASAS5/6、ASDAS-CRP、BASDAI及SF-36改善呈中度至强相关。

关键数值与推荐

  • 疲劳应答定义为FACIT-F改善≥4(观察数据)。
  • 第16周FACIT-F改善较安慰剂显著(P<0.05)。
  • 第16周疲劳应答率司库奇尤单抗组高于安慰剂(MEASURE 1 P<0.05;MEASURE 2 P<0.01)。

临床怎么用

  • 司库奇尤单抗可用于改善活动性强直性脊柱炎患者疲劳,且疗效可持续长达3年。
  • 既往抗TNF暴露不影响司库奇尤单抗的疲劳改善效果。

局限性

  • 基线特征未能一致预测疲劳改善。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate the longer-term effects of secukinumab 150 mg on fatigue in patients with ankylosing spondylitis (AS) in the MEASURE 1 study (up to 3 years) and the MEASURE 2 study (up to 2 years). METHODS: Patients with active AS were randomized to secukinumab or placebo in MEASURE 1 (10 mg/kg intravenous [IV] followed by 150 mg subcutaneous) and MEASURE 2 (150 mg subcutaneous). Patients were naive to treatment with anti-tumor necrosis factor (anti-TNF-naive) therapy or had an inadequate response/intolerance to anti-TNF therapy (anti-TNF-IR). Fatigue was measured using the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) scale. Relationships between fatigue response and baseline characteristics and clinical/laboratory variables were explored. RESULTS: Significant improvements in FACIT-F scores from baseline were observed with secukinumab across both studies versus placebo at week 16 (P < 0.05). Improvements were sustained through week 156 (MEASURE 1) and week 104 (MEASURE 2). Significantly more patients reported fatigue responses (FACIT-F improvement ≥4; observed data) with secukinumab 150 mg than with placebo at week 16 in both MEASURE 1 (P < 0.05) and MEASURE 2 (P < 0.01). Fatigue responses were achieved by 75.6% of patients receiving secukinumab at week 156 (MEASURE 1) and 81.4% at week 104 (MEASURE 2); these results were consistent in patients who were anti-TNF-naive (74.3% and 84.6%, respectively) and anti-TNF-IR (81.3% and 75.0%, respectively). Baseline characteristics did not predict improvement in fatigue consistently. Fatigue responses were moderately to strongly correlated with responses in several clinical measures, including the Assessment of SpondyloArthritis international Society (ASAS) 20%/40% improvement, ASAS5/6 responses, the Ankylosing Spondylitis Disease Activity Score with C-reactive protein level, the Bath Ankylosing Spondylitis Disease Activity Index, and the Short Form 36 health questionnaire scores. CONCLUSION: Secukinumab provided rapid and sustained improvements in fatigue for up to 3 years, regardless of prior anti-TNF exposure.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Kvien TK, Conaghan PG, Gossec L, et al. Secukinumab and Sustained Reduction in Fatigue in Patients With Ankylosing Spondylitis: Long-Term Results of Two Phase III Randomized Controlled Trials. Arthritis Care Res (Hoboken). 2022. PMID: 33227175. doi:10.1002/acr.24517

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。